Allakos Announced A Poster Presentation At The 2024 American Academy Of Allergy, Asthma & Immunology Annual Meeting. The Poster Highlights Preclinical Data Detailing AK006's Mechanism Of Action And Ability To Reduce MRGPRX2-induced Skin Inflammation

2/26/24 7:18:09 AM ET

$ALLK

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALLK alert in real time by email

Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages –
AK006 inhibited mast cell activation and reduced mast cell numbers in an MRGPRX2-induced skin inflammation model

Get the next $ALLK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ALLK

Date	Price Target	Rating	Analyst
1/17/2024	$6.00 → $1.50	Buy → Hold	Jefferies
1/16/2024		Overweight → Neutral	Cantor Fitzgerald
12/18/2023		Mkt Perform → Outperform	William Blair
12/8/2023	$9.00 → $6.00	Buy	Jefferies
9/27/2023	$11.00	Mkt Outperform	JMP Securities
5/12/2023	$6.00 → $9.00	Hold → Buy	Jefferies
3/7/2023	$22.00	Overweight	Piper Sandler
9/12/2022	$2.00	Neutral → Underperform	SMBC Nikko

More analyst ratings

$ALLK
Press Releases

Fastest customizable press release news feed in the world

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in early Q1 of 2025 – SAN CARLOS, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced results from the Phase 1 study of subcutaneous AK006 in healthy volunteers. AK006 is a Siglec-6 monoclonal antibody that selectively inhibits mast cells. Inappropriate activation of mast cells has been identi
10/10/24 4:02:00 PM ET
$ALLK
Biotechnology: Pharmaceutical Preparations
Health Care
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2024. Recent Allakos Events Initiated the randomized, double-blind, placebo-controlled Phase 1 trial of intravenous (IV) AK006 in patients with chronic spontaneous urticaria.Completed dosing in the randomized, double-blind, placebo-controlled subcutaneous (SC) AK006 cohort in healthy volunteers.Reported safety, pharmacokinetics (PK), and pharmacodynamic (PD) results f
8/7/24 4:02:00 PM ET
$ALLK
Biotechnology: Pharmaceutical Preparations
Health Care
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was well-tolerated with a favorable safety profile – SAN CARLOS, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced positive results from the single and multiple ascending Phase 1 study of intravenous (IV) AK006 in healthy volunteers. AK006 is a Siglec-6 monoclonal antibody that selectively inhibits mast cells. Inappropriate activation of mast cells has been id
6/25/24 4:02:00 PM ET
$ALLK
Biotechnology: Pharmaceutical Preparations
Health Care

Allakos Appoints Neil Graham to its Board of Directors
SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan Pharmaceuticals Limited, Pharmaxis Limited and Zura Bio Limited. Among other experiences, Dr. Graham was the Vice President of Strategic Program Direction, Immunology and Inflammation at Regeneron Ph
8/30/23 4:05:00 PM ET
$ALLK
Biotechnology: Pharmaceutical Preparations
Health Care
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and currently serves on the board of directors of Krystal Biotech, Inc. and Vanqua Bio, Inc. Among other experiences, Dr. Sutherland held senior roles developing therapeutics at Translate Bio, Inc. as well
8/2/23 4:05:00 PM ET
$ALLK
Biotechnology: Pharmaceutical Preparations
Health Care
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at Stanford University, to the Allakos board of directors. "We are very pleased to have such an accomplished physician as Dr. Ladd join our board. Her extensive medical background and expertise will provide valuable insights as we continue to advance lirentelimab and our novel pipeline through clinical trials," said Robert Alexander, Ph.D., the Company's Chief Executive Officer. Dr. L
7/25/22 4:05:00 PM ET
$ALLK
Biotechnology: Pharmaceutical Preparations
Health Care

Allakos Announced A Poster Presentation At The 2024 American Academy Of Allergy, Asthma & Immunology Annual Meeting. The Poster Highlights Preclinical Data Detailing AK006's Mechanism Of Action And Ability To Reduce MRGPRX2-induced Skin Inflammation

Chat with this insight

Recent Analyst Ratings for $ALLK

$ALLK Press Releases

Fastest customizable press release news feed in the world

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

$ALLK Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Allakos Inc.

Amendment: SEC Form SC 13G/A filed by Allakos Inc.

SEC Form SC 13G/A filed by Allakos Inc. (Amendment)

$ALLK Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$ALLK Leadership Updates

Live Leadership Updates

$ALLK SEC Filings

Allakos downgraded by Jefferies with a new price target

Allakos downgraded by Cantor Fitzgerald

Allakos upgraded by William Blair

Allakos Appoints Neil Graham to its Board of Directors

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

Allakos Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

SEC Form 10-Q filed by Allakos Inc.

Allakos Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ALLK Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Alexander Robert covered exercise/tax liability with 37,311 shares, decreasing direct ownership by 4% to 801,940 units (SEC Form 4)

Chief Medical Officer Lee Chin Hyok covered exercise/tax liability with 45,320 shares, decreasing direct ownership by 14% to 285,680 units (SEC Form 4)

Chief Financial Officer Radford Harlan Baird covered exercise/tax liability with 13,665 shares, decreasing direct ownership by 7% to 190,725 units (SEC Form 4)

$ALLK Market Insights

Live Market Insights

Jefferies Maintains Hold on Allakos, Lowers Price Target to $1

JMP Securities Reiterates Market Outperform on Allakos, Maintains $3 Price Target

Allakos shares are trading lower. The company announced results from the single and multiple ascending Phase 1 study of intravenous AK006 in healthy volunteers.

$ALLK Financials

Live finance-specific insights

Allakos Announces a Restructuring to Focus on Development of AK006

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

Recent Analyst Ratings for
$ALLK

$ALLK
Press Releases

$ALLK
Large Ownership Changes

$ALLK
Analyst Ratings

$ALLK
Leadership Updates

$ALLK
SEC Filings

$ALLK
Insider Trading

$ALLK
Market Insights

$ALLK
Financials